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based on a societal perspective, was assessed for women with
menopausal symptoms. METHODS: An individual state transi-
tion model populated Swedish data was used to estimate the
cost-effectiveness of women with menopausal symptoms. The
model consists of the following disease states: Coronary Heart
Disease (CHD), Stroke, Venous thromboembolic events (VTE),
breast cancer, colorectal cancer, hip fracture, vertebral fracture
and wrist fracture. HRT therapy was modelled by its impact on
the disease risks during therapy and possible effects after the ces-
sation of therapy. The model calculates costs and health effects
or quality adjusted life years (QALYs) with and without inter-
vention. The resulting cost per gained QALY was compared to
the value of a gained QALY, which was set to 65,000€.
RESULTS: The cost per QALY gained for Swedish women with
intact uterus and menopausal symptoms were estimated to
1404€, 1188€, and 1004€ when the therapy started at the age of
50, 55, and 60, respectively. The cost per QALY gained was
found to be below the set value of a QALY at very low symptom
related reductions in the quality of life. CONCLUSIONS: The
results indicate that there is high probability that HRT is 
cost-effective for the treatment of women with menopausal
symptoms.
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ACUTE COSTS OF STROKE IN THE UK NATIONAL HEALTH
SERVICE IN 2002–2004
Luengo-Fernandez R1, Gray A1, Mehta Z2, Rothwell P2
1Oxford University, Oxford, Oxfordshire, UK; 2Oxford University, UK
OBJECTIVE: Stroke is a major cause of morbidity, health service
use, and death in the UK. Previous studies report substantial
associated costs, particularly related to hospitalisation. However,
no previous UK analysis has used data from a population-based
incidence study with full case ascertainment, without which
major inclusion bias is likely. Using data from such a study, we
estimate the acute costs per patient over the ﬁrst year from initial
stroke, by severity of stroke and prior atrial ﬁbrillation.
METHODS: Event and hospitalisation (inpatient or outpatient)
data were obtained from the Oxford Vascular Study, a prospec-
tive cohort study of all individuals in 9 general practices in
Oxfordshire, UK, which identiﬁed 346 patients experiencing a
stroke from April 1, 2002–March 31, 2004. Transient ischaemic
attacks were excluded. Mean costs per patient were calculated,
adjusting for censoring. RESULTS: In all, 212 (62%) patients
were admitted, the remainder being managed in the outpatient
clinic. The mean censoring-adjusted cost per patient was
GBP6508, 69% of which was incurred within 60 days after the
index event. Patients with stroke recurrence in the study period
incurred costs of £7881 compared to GBP6089 in those without.
Costs in patients with prior atrial ﬁbrillation were £9757, com-
pared with £5687 in those without (p = 0.028). Patient costs by
stroke severity (28-day Rankin score 0/1 = mild, 2/3 = moder-
ate, 4/5 = severe, 6 = dead) were £1138, £7471, £18181, and
£1602. CONCLUSIONS: We derived reliable and up-to-date
estimates of acute care costs associated with stroke over the ﬁrst
12 months, using data from an “ideal” population-based inci-
dence study. The impact of severity of initial stroke and of prior
atrial ﬁbrillation on subsequent costs. Our estimates, which will
be extended as follow-up continues, should be of value to ana-
lysts interested in assessing the burden of stroke and the cost-
effectiveness of interventions.
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PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
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OBJECTIVES: Beta-blockers have provided evidence of improv-
ing survival in chronic heart failure (CHF) patients. Speciﬁcally,
the Cardiac Insufﬁciency Bisoprolol Study II (CIBIS-II) has
demonstrated a signiﬁcant reduction in mortality and morbidity
among patients with moderate to severe CHF treated with biso-
prolol. Our aim was to investigate the economic consequence of
bisoprolol therapy in CHF patients in Italy. METHODS: Data
were derived from the CIBIS-II trial. We conducted a cost-
effectiveness analysis, comparing standard care + bisoprolol vs
standard care + placebo in the perspective of the Italian National
Health Service (NHS). We identiﬁed and quantiﬁed medical
costs: drug costs according to the Italian market price; specialist
visits for initiation and up-titration of bisoprolol therapy and
hospitalizations were quantiﬁed on the basis of the NHS tariffs
(2004). Effects were measured in terms of mortality and mor-
bidity reduction (number of deaths, life years saved and fre-
quency of hospitalizations). We considered an observational
period of 1.3 years that was the average follow-up recorded in
the trial. Discounting was not performed because of the relatively
short follow-up of patients. We conducted one-way sensitivity
analyses on unit cost and effectiveness. RESULTS: The overall
cost of care per 1000 patients treated for 1.3 years was estimated
in 2,043,700€ in the bisoprolol group and in 2,366,168€ in the
placebo group, resulting in a net saving of 322,468€. The
number of additional patients alive with bisoprolol was 55 per
1000 patients, the number of LYS was 36 at 1.3 year. CON-
CLUSION: Bisoprolol therapy is dominant since it is both less
costly and more effective than standard care. Results of sensi-
tivity analysis showed that bisoprolol therapy remains dominant
even to changes in unit cost of drug, hospitalizations and fre-
quency of hospital admissions.
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OBJECTIVES: The effectiveness of smoking cessation (SC) in the
reduction of cardiovascular disease (CVD) risk is demonstrated.
However, different options exist with variable levels of costs and
effects and which one to choose for primary prevention of CVD
is unclear. We evaluated the cost-effectiveness of different strate-
gies of SC. METHODS: Using data from the Framingham Heart
Study and the Framingham Offspring Study we built multistate
life tables to model the cost-effectiveness of different SC thera-
pies (Nurse or GP advice, nicotine substitutes (with or without
GP guidance), buproprion and a combination of buproprion and
nicotine substitutes) in male smokers free of CVD at baseline and
aged between 45 and 65. Participants were categorized in terms
of 10 years absolute risk of coronary heart disease (based on the
Anderson Formulae) and age. Cessation rates, risk reduction
rates for CVD and relapse rates were taken from the literature.
We calculated the cost-effectiveness in terms of costs per year of
life saved (LYS) using a time horizon of 5 and 10 years. A third-
party payer perspective was used and cost and effects were dis-
counted at 4%. Costs were estimated either by tariffs or market
prices and costs of prevented events were taken from the litera-
ture. Finally, we compared the strategies in an (incremental) cost-
effectiveness analysis. RESULTS: Costs per LYS for all strategies
were negative at all levels of risk and age groups. SC with GP
advice was most favourable, ranging from -4919€ to -3187€
and SC with buproprion the least (-3460€, -1215€). In the in-
cremental analysis SC with nicotine substitutes alone is to be 
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preferred (for all groups) followed by buproprion. CONCLU-
SIONS: Smoking cessation is a very cost-effective intervention
for primary prevention of CVD and should be offered ﬁrst to the
smoking populations, before other interventions are considered.
PCV26
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OBJECTIVES: To compare the cost-effectiveness of extended
antithrombotic prophylaxis using low-molecular-weight heparin
(LMWH), warfarin or aspirin with no extended prophylaxis fol-
lowing total hip arthroplasty in terms of incremental cost per life
year gained. METHODS: Health beneﬁts of extended antithrom-
botic prophylaxis, measured as the reduction in symptomatic
venous thromboembolic (VTE) events and deaths for each treat-
ment alternative, were determined through a meta-analysis of the
literature. Potential years of life lost per VTE death was based
on mean life years remaining for the age distribution of all
patients undergoing total hip arthroplasty in Canada in 2003.
Costs included retail drug costs, administration and monitoring
costs of extended prophylaxis and costs of diagnosing and man-
aging VTE or bleeding events developing within three months of
surgery. The economic analysis used probabilistic modeling
structured around a decision tree characterizing extended pro-
phylaxis choices following total hip arthroplasty. RESULTS: No
studies reported a statistically signiﬁcant effect for aspirin so it
was excluded from the reference scenario. The reference scenario
assumes 50 percent of LMWH and warfarin patients require
home visits for injections or INR monitoring. Probabilistic sim-
ulations found positive life years (LY) gained in the LMWH and
warfarin cohorts relative to no extended prophylaxis (LMWH =
6.9LY gained per 1000 treated; warfarin = 5.5/1000). Net treat-
ment costs were highest in the LMWH cohort at US$742,983
per 1000. LMWH costs were extremely sensitive to the propor-
tion of the cohort receiving home care. Net costs with warfarin
were US$70,540 per 1000 and were much less sensitive to home
visit proportions. The incremental cost-effectiveness ratio (ICER)
of warfarin relative to no further prophylaxis is US$12,778 per
LY gained, while LMWH relative to warfarin is US$475,159.
CONCLUSIONS: The cost-effectiveness of warfarin is quite
favourable relative to generally accepted thresholds. LMWH is
beyond what would be considered cost-effective, even at the
lowest home care proportions.
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OBJECTIVES: To evaluate short (12 months) and long term
cost-effectiveness (CE) of smoking cessation therapies
(willpower, physician advice, nicotine replacement therapies
[NRT/inhaler/patch/gum/tablets/spray] and bupropion [BUP]) in
Finland. METHODS: A decision analytic model was constructed
and analysed from societal viewpoint. Costs included direct
costs. Drug prices were retail prices excluding taxes. Drug dosing
followed recommendations. Prescription medicine treatments
(Rx; NRT/spray, BUP) included the cost of 2 physician visits.
Adverse event incidence was assumed 1% in pharmacotherapies.
Short term effectiveness (probability to quit) was estimated from
those studies included in Cochrane reviews of smoking cessation
that fulﬁlled the inclusion criteria (12 months of continuous
abstinence; OTC: level of support low; Rx: level of support low
or high, no group therapy) using Mantel-Haenszel weights.
Long-term effectiveness (life years saved, LYS) was estimated
from age speciﬁc differences in life expectancies between smokers
and quitters. RESULTS: In the short-term BUP dominated all
pharmacotherapies (NRTs), and its cost/quitter was the lowest
(1167€), disregarding willpower. The incremental cost/quitter
was 1060–1220€ compared to non-pharmacotherapies. In the
long term, BUP cost/LYS was the lowest (365€). After 3% dis-
counting of health beneﬁts (LYS) BUP cost/LYS was 898€. The
BUP incremental cost/LYS as compared to non-pharmacothera-
pies was 330–380€ (discounted 820–940€). Sensitivity analyses
(effectiveness, adverse events) did not produce changes in BUP’s
positioning among cessation therapies. CONCLUSIONS: In
Finland, BUP is a cost-effective alternative in smoking cessation
in short and long-term compared to many other health care 
interventions.
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OBJECTIVES: Ramipril may prevent cardiovascular death,
myocardial infarction, and stroke in patients without evidence
of left ventricular dysfunction or heart failure who are at high
risk for cardiovascular events. In the present study, we assessed
the cost-effectiveness of ramipril in patients with an increased
risk of cardiovascular events from a third-party payer’s perspec-
tive in Switzerland. In addition, the cost-effectiveness of ramipril
in the subgroup of diabetic patients was assessed. METHODS:
We developed a decision analytic cost-effectiveness model to 
estimate the incremental costs (in 2001 Swiss Francs [CHF]),
incremental effects (in terms of life-years gained [LYG]) and
incremental cost-effectiveness (CHF/LYG) of ramipril versus
placebo. Clinical input parameters were derived from the Heart
Outcomes Prevention Evaluation (HOPE) study. Cost data were
extracted from the literature. Deterministic sensitivity analysis
was used to assess the impact of varying the input parameters
on the cost-effectiveness of the intervention. In addition, ﬁrst-
order Monte Carlo simulation was used to capture patient-to-
patient variability, presented as cost-effectiveness acceptability
curves. RESULTS: The incremental cost-effectiveness ratio of
ramipril versus placebo was CHF 6005 per life-year gained in
the base case analysis. In diabetic patients the cost-effectiveness
ratio was CHF 3790 per life-year gained. Varying the price of
ramipril in a deterministic sensitivity analysis only had a mod-
erate impact on the cost-effectiveness ratio in the overall popu-
lation (range: CHF 3652–15,418/LYG) as well as in diabetic
patients (range: CHF 2370–9468/LYG). CONCLUSIONS:
Ramipril in patients at high risk for cardiovascular events 
represents an efﬁcient use of scarce health care resources in
Switzerland and is cost-effective under reasonable assumptions.
Ramipril is even more cost-effective in the subgroup of diabetic
patients.
